

## BRAF CODON 600 VARIANT ANALYSIS

Patient Details		Source Information		Sample Information	
Lab Number:	MP17-5874	Requester Ref:		Date Received:	01/08/2017
Surname:	Atient	Surgical No.:	323/13	Primary Tumour Site:	Skin
Forename:	Peter	Sample Type	FFPE Block	Tumour Subtype:	Nodular Melanoma
D.O.B. (D/M/Y)	10/12/1976	Consultant:	Smith	Tissue Sample Site:	Skin
Gender:	Male	Hospital:	Random DGH	(Whole):	21-50%
				% Tumour (Selected):	

### Results

**Detected DNA Change:** c.1799T>A or c.1799\_1800delinsAA

**Detected Protein Change:** p.(Val600Glu)

#### Mutation Status Summary:


There is evidence of BRAF p.(Val600Glu) mutation in this sample, this mutation indicates an increased likelihood of response to BRAF-targeted treatment.

#### Other Comments:

None

#### Approved by:

Signature:



Name: \_\_\_\_\_ Date: 01/08/2017

Job Title: Dr F. Irst


Clinical Scientist ✓

Consultant Histopathologist

BMS (senior)

#### Checked by:

Signature:



Name: \_\_\_\_\_ Date: 01/08/2017

Job Title: Dr S. Econd

BMS

Trainee Clinical Scientist

Trainee BMS

Molecular Biology, PhD ✓

This assay was performed on a Qiagen RotorGene-Q QPCR system using the Therascreen BRAF RGQ PCR Kit. This assay is CE-IVD certified for use on samples with >5% tumour content, with an analytical sensitivity of approximately 5% variant frequency and can detect the following mutations; p.Val600Glu (c.1799T>A or c.1799\_1800delinsAA), p.Val600Asp (c.1799\_1800delinsAT), p.Val600Lys (c.1798\_1799delinsAA), and p.Val600Arg (c.1798\_1799delinsAG). All DNA and Protein changes are given with respect to BRAF reference sequence NM\_004333.4.